Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Sherief Abd-Elsalam

Status and phase: Unknown; Phase 3

Conditions: Diabetes

Treatments: Drug: Cabergoline; Drug: Gliclazide

Study type: Interventional

Funder types: Other

Identifiers

NCT03313661

Diabetes Mellitus

Details and patient eligibility

About

Evaluation of the glycemic efficacy of cabergoline on diabetic patients

Full description

Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is a fundamental part of the management of type 2 DM and difficult to achieve. Different antidiabetic agents can handle diabetic metabolic abnormalities. The development of antidiabetic agentswith novel mechanisms of action is highly desirable. Cabergoline, a long acting D2 agonist, is expected to play a role in the glycemic control.

Enrollment: 60 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Diabetic patients.

Exclusion criteria

• Other drugs administration

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 3 patient groups

Cabergoline

Experimental group

Description:

cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide

Treatment:

Drug: Cabergoline

Gliclazide

Active Comparator group

Description:

gliclazide (60-120 mg) once daily

Treatment:

Drug: Gliclazide

Placebo

No Intervention group

Description:

Placebo